ONC201 in Recurrent H3 K27M-mutant Diffuse Midline Glioma

Time: 12:30 pm
day: Conference Day One

Details:

  • Overview of ONC201 discovery and early clinical development
  • Review of efficacy signal refinement for ONC201 toward H3 K27M-mutant glioma
  • Summary of ONC201 efficacy it recurrent H3 K27M-mutant diffuse midline glioma

Speakers: